Abstract
Despite the continuing threats of the global noncommunicable diseases (NCDs) epidemic, the funding agenda for disruptive innovation remains pale, particularly for cancer research and development. Chief among the NCDs, cancer stands in dire straits. Over the last decade, the global cancer burden has shifted from the developed world to the less developed countries. In developing countries, 56 % of cancer cases and 64 % of cancer deaths occurred. Worrisomely, cancer survival rates are much lower in developing countries due to the difficulties in early diagnosis, first clinical presentation as advanced disease, and, importantly, lack of disruptive innovation for new diagnostics and therapeutics. Several promising cancer research endeavors are merely shelved due to the paucity of adequate long-term or rapid response financial aid to developing world cancer researchers. Alternative sources of research funding, too, are limited in less developed countries, causing a “double jeopardy” in cancer research funding. Despite their vast population sizes in the order of billions, contribution of the philanthropic sector for cancer research is very infrequent in India and the mainland China. Disruptive innovation in cancer research will not come to fruition unless we are willing to innovate “upstream” first, at the level of research funding. Angel philanthropy tends to fund research with higher risks for failure but with greater odds for disruptive innovation. We propose that the local angel philanthropy networks may provide the necessary boost to create disruptive innovation ecosystems for cancer research in the developing world.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
[No authors listed] (2011) Two days in New York: reflections on the UN NCD summit. Lancet Oncol 12:981. doi: 10.1016/S1470-2045(11)70272-8
Are C, Rajaram S, Are M et al (2013) A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol 107:221–226. doi:10.1002/jso.23248
Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013) Tumour heterogeneity in the clinic. Nature 501:355–364. doi:10.1038/nature12627
Chen R, Mias GI, Li-Pook-Than J et al (2012) Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148:1293–1307. doi:10.1016/j.cell.2012.02.009
Cheng MH (2007) Cancer research funding in Asia. Mol Oncol 1:135–137
Eckhouse S, Sullivan R (2006) A survey of public funding of cancer research in the European union. PLoS Med 3:e267
Eckhouse S, Lewison G, Sullivan R (2008) Trends in the global funding and activity of cancer research. Mol Oncol 2:20–32. doi:10.1016/j.molonc.2008.03.007
Farmer P, Frenk J, Knaul FM et al (2010) Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 376:1186–1193. doi:10.1016/S0140-6736(10)61152-X
Fernandez JM, Stein RM, Lo AW (2012) Commercializing biomedical research through securitization techniques. Nat Biotechnol 30:964–975
Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
Kanavos P (2006) The rising burden of cancer in the developing world. Ann Oncol 17(Suppl 8):viii15–viii23
Lingwood RJ, Boyle P, Milburn A et al (2008) The challenge of cancer control in Africa. Nat Rev Cancer 8:398–403. doi:10.1038/nrc2372
Marko NF (2013) The cancer megafund: determinants of success. Nat Biotechnol 31:492–494. doi:10.1038/nbt.2603
Masters (2013) Is it time for the public to start funding cancer research? The telegraph. Available from http://www.telegraph.co.uk/news/health/10120853/Is-it-time-for-the-public-to-start-funding-cancerresearch.html
Network TC (2013) Corrigendum: comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 494:506. doi:10.1038/nature11903
Özdemir V, Badr KF, Dove ES et al (2013) Crowd-funded micro-grants for genomics and “big data”: an actionable idea connecting small (artisan) science, infrastructure science, and citizen philanthropy. OMICS 17:161–172. doi:10.1089/omi.2013.0034
Rastogi T, Hildesheim A, Sinha R (2004) Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer 4:909–917
Ray S, Moiyadi A, Srivastava S (2013) Epidemiology: biorepositories for cancer research in developing countries. Nat Rev Clin Oncol 10:434–436. doi:10.1038/nrclinonc.2013.119
Roychowdhury S, Lyer MK, Robinson DR et al (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3:111ra121. doi:10.1126/scitranslmed.3003161
Vayena E, Prainsack B (2013) The challenge of personal genomics in Germany. Nat Biotechnol 31:16–17. doi:10.1038/nbt.2469
Acknowledgements
This study was supported by the Department of Biotechnology, India grant (No. BT/PR14359/MED/30/916/2010 and BT/PR13562/MED/12/451/2010) to SS.
Competing Interests
The authors declare no competing interests.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer India
About this chapter
Cite this chapter
Ray, S., Özdemir, V. (2016). Angel Philanthropy and Crowdfunding to Accelerate Cancer Research in Developing World. In: Srivastava, S. (eds) Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2837-0_5
Download citation
DOI: https://doi.org/10.1007/978-81-322-2837-0_5
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2835-6
Online ISBN: 978-81-322-2837-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)